AC
ARKG icon

AlphaCore Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

AlphaCore Capital’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93K Buy
236
+100
+74% +$3.19K ﹤0.01% 1397
2026
Q1 		$3.59K Sell
136
-1,200
-90% -$35.1K ﹤0.01% 1149
2025
Q4 		$38.7K Buy
+1,336
New +$40.1K ﹤0.01% 1188

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

AlphaCore Capital's ARKG Position: Q2 2026 in Review

AlphaCore Capital increased its ARK Genomic Revolution ETF (ARKG) stake by 74% in Q2 2026, buying an estimated $3.19K and bringing the position to 236 shares worth $9.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

AlphaCore Capital first reported a position in ARKG in Q4 2025 and has held it in 3 quarters since. The position peaked at $38.7K in Q4 2025. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • AlphaCore Capital held 236 shares of ARK Genomic Revolution ETF worth $9.93K as of Q2 2026.
  • AlphaCore Capital bought 100 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $3.19K.
  • ARK Genomic Revolution ETF made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1397 holding.
  • AlphaCore Capital first reported a position in ARK Genomic Revolution ETF in Q4 2025 and has held it in 3 quarters since.
  • AlphaCore Capital's ARK Genomic Revolution ETF position peaked at $38.7K in Q4 2025.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.